Program
BR1400-3
A development code.
Its studies are mostly in Essential Hypertension, led by Boryung Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boryung Pharmaceutical | 21 open or running | phase 2since Jan 20, 2026 | Mar 17, 2025 | Feb 1, 2027phase 2 · NCT07373613 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 17, 2025First study: phase 1 study in Essential HypertensionFirst studyNCT06889064 · 28 enrolled · Korea, Republic of
- Jan 20, 2026Phase 2 study in Essential HypertensionPhase 2 reachedNCT07373613 · 330 planned · South Korea
Ahead
- Feb 1, 2027Primary completion: phase 2 study in Essential HypertensionNCT07373613
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07373613Essential Hypertension · South Korea | 2 | Not yet recruiting | Feb 1, 2027 | 330 |
| NCT06889064Essential Hypertension · Korea, Republic of | 1 | Completed | Oct 8, 2024 | 28 |
How it is read
Names in the registry
- “BR1400-3”, 2 entries
Codes read as this program: BR14003.
Conditions, from the studies’ own filings
- Essential Hypertension, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.